How Novo Nordisk Makes its Money: Revenue Breakdown
A breakdown of Novo Nordisk (NVO) financials. See how Novo Nordisk makes money from Ozempic, Wegovy, insulin, and GLP-1 therapies using their 2024 annual report.
How Does Novo Nordisk Make its Money?
Novo Nordisk is a Danish pharmaceutical company and the world leader in diabetes care and obesity treatment. The company has been transformed by the explosive success of its GLP-1 receptor agonist drugs — Ozempic (for type 2 diabetes) and Wegovy (for obesity/weight management) — which have become the most in-demand medicines in the world.
Founded in 1923, Novo Nordisk built its business on insulin and has been the global market leader in diabetes care for decades. The GLP-1 revolution has taken the company to an entirely new level, with semaglutide (the active ingredient in Ozempic and Wegovy) demonstrating benefits not just for blood sugar control and weight loss, but potentially for cardiovascular disease, kidney disease, fatty liver disease, and sleep apnea.
Novo Nordisk (NVO) Business Model
Novo Nordisk operates in the pharmaceuticals sector. Below is a summary of Novo Nordisk’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Novo Nordisk’s 2024 fiscal year filings with the SEC.
Novo Nordisk Competitors
Novo Nordisk’s key competitors and comparable public companies in the pharmaceuticals sector include Eli Lilly, Pfizer, and Hims and Hers. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Novo Nordisk stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Product/Category | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Ozempic | DKK 140.0B | DKK 99.0B | +41.4% |
| Wegovy | DKK 51.0B | DKK 31.3B | +62.9% |
| Other GLP-1 (Victoza, Rybelsus) | DKK 22.0B | DKK 23.5B | -6.4% |
| Insulin (Tresiba, NovoRapid, etc.) | DKK 53.0B | DKK 51.0B | +3.9% |
| Other Diabetes & Obesity | DKK 12.0B | DKK 10.5B | +14.3% |
| Rare Disease (Hemophilia, etc.) | DKK 12.5B | DKK 12.0B | +4.2% |
| Total Revenue | DKK 290.4B (~$42B) | DKK 232.3B (~$34B) | +25.0% |
Ozempic — 48% of Revenue
A once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. Ozempic has become one of the best-selling drugs in pharmaceutical history, with revenue growing 41% year-over-year. The drug is also widely prescribed off-label for weight loss, though its official indication is diabetes. Ozempic’s success is driven by its efficacy (average 15% body weight reduction), favorable cardiovascular outcomes, and massive direct-to-consumer advertising.
Wegovy — 18% of Revenue
The same semaglutide molecule as Ozempic but dosed and approved specifically for chronic weight management. Wegovy is the first drug to demonstrate that pharmacological weight loss reduces heart attack and stroke risk by 20% (the SELECT trial). This indication has expanded the addressable market enormously — an estimated 100+ million adults in the U.S. alone could qualify. Wegovy supply has been constrained since launch, and Novo Nordisk is investing billions to expand manufacturing capacity.
Insulin — 18% of Revenue
Novo Nordisk’s legacy business and still a significant revenue contributor. Key products include Tresiba (long-acting), NovoRapid (rapid-acting), and the new once-weekly insulin icodec (Awiqli). The insulin portfolio provides a stable base while GLP-1 products drive growth.
Rare Disease — 4% of Revenue
Hemophilia treatments (NovoSeven, Esperoct) and growth hormone disorders. A smaller but profitable business.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | DKK 290.4B | DKK 232.3B |
| Cost of Goods Sold | DKK 66.4B | DKK 51.6B |
| Gross Profit | DKK 224.0B | DKK 180.7B |
| Operating Expenses | DKK 103.0B | DKK 82.0B |
| Operating Income | DKK 121.0B | DKK 98.7B |
| Net Income | DKK 91.0B (~$13.2B) | DKK 83.7B (~$12.1B) |
Financial data sourced from Novo Nordisk SEC Filings.
Key Financial Metrics
- Gross Margin: 77.1% — Outstanding, reflecting the high value of patented biological medicines. Manufacturing biologics is complex but the pricing power is enormous.
- Operating Margin: 41.7% — Among the highest in all of pharma. Novo Nordisk’s pricing authority and scale in GLP-1 production drive extraordinary profitability.
- Revenue Growth: +25.0% — Exceptional for a company of this size. Growth was constrained by manufacturing capacity rather than demand — the real demand for semaglutide likely exceeds what Novo Nordisk can currently produce.
- Capex: DKK 40B+ — Novo Nordisk is investing aggressively in manufacturing expansion, including filling/finishing capacity and API (active pharmaceutical ingredient) production. The capex bill reflects the scale of the GLP-1 opportunity.
Is Novo Nordisk Profitable?
Yes, Novo Nordisk is exceptionally profitable, reporting DKK 91B (~$13.2B) in net income on DKK 290.4B (~$42B) in revenue. The 41.7% operating margin is among the highest in the entire pharmaceutical industry, reflecting the pricing power of Ozempic and Wegovy, the relatively low manufacturing cost of injectable biologics at scale, and Novo Nordisk’s dominant market position. The company generates massive free cash flow and returns significant capital to shareholders through dividends and buybacks. Profitability would be even higher if not for the enormous capex investment ($6B+) in manufacturing expansion to meet semaglutide demand.
What to Watch
- GLP-1 competition — Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is the primary competitor and has shown slightly greater weight loss in some trials. The GLP-1 market is likely big enough for both, but market share dynamics between Novo Nordisk and Lilly will significantly impact revenue.
- Manufacturing capacity — Supply has been the binding constraint on Wegovy and Ozempic revenue. Novo Nordisk’s ability to scale manufacturing will directly determine growth trajectory for the next 2-3 years.
- Insurance coverage expansion — Medicare, Medicaid, and private insurers are gradually expanding GLP-1 coverage for obesity. Every coverage expansion dramatically increases the accessible patient population.
- Oral semaglutide — Rybelsus is the oral form of semaglutide. Higher-dose oral semaglutide in development could be a game-changer by eliminating the need for injections, making the drug more accessible.
- Next-generation molecules — Novo Nordisk has amycretin (a next-gen molecule showing ~22% weight loss) and CagriSema (combined semaglutide + cagrilintide) in clinical trials. These could sustain growth beyond semaglutide’s eventual patent expiration.
Novo Nordisk (NVO) Financial Summary
Novo Nordisk (NVO) is the world’s leading diabetes and obesity pharmaceutical company, generating DKK 290.4B (~$42B) in revenue in fiscal year 2024, growing 25% year-over-year. Ozempic ($20.3B) and Wegovy ($7.4B) drove the majority of growth. The company earned DKK 91B (~$13.2B) in net income with industry-leading 41.7% operating margins. For a deeper look at Novo Nordisk’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.